Hence, routine assessment for A1AT deficiency using serum A1AT levels of patients with solely HCV-related liver disease seems less promising to identify patients at risk of developing progressive liver injury. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.